181 related articles for article (PubMed ID: 10229966)
1. [Entacapone++ : a new catechol-O-methyltransferase inhibitor which improves the response to levodopa in patients with Parkinson disease and fluctuating motor function].
Horga de la Parte JF
Rev Neurol; 1999 Mar 1-15; 28(5):499-504. PubMed ID: 10229966
[TBL] [Abstract][Full Text] [Related]
2. New options for treatment of Parkinson's disease.
LeWitt PA
Baillieres Clin Neurol; 1997 Apr; 6(1):109-23. PubMed ID: 9426871
[TBL] [Abstract][Full Text] [Related]
3. Entacapone, a catechol-O-methyltransferase inhibitor, improves the motor activity and dopamine content of basal ganglia in a rat model of Parkinson's disease induced by Japanese encephalitis virus.
Hamaue N; Ogata A; Terado M; Tsuchida S; Yabe I; Sasaki H; Hirafuji M; Togashi H; Aoki T
Brain Res; 2010 Jan; 1309():110-5. PubMed ID: 19879254
[TBL] [Abstract][Full Text] [Related]
4. Fewer fluctuations, higher maximum concentration and better motor response of levodopa with catechol-O-methyltransferase inhibition.
Muhlack S; Herrmann L; Salmen S; Müller T
J Neural Transm (Vienna); 2014 Nov; 121(11):1357-66. PubMed ID: 24770794
[TBL] [Abstract][Full Text] [Related]
5. Catechol-O-methyltransferase inhibition with tolcapone reduces the "wearing off" phenomenon and levodopa requirements in fluctuating parkinsonian patients.
Baas H; Beiske AG; Ghika J; Jackson M; Oertel WH; Poewe W; Ransmayr G
J Neurol Neurosurg Psychiatry; 1997 Oct; 63(4):421-8. PubMed ID: 9343116
[TBL] [Abstract][Full Text] [Related]
6. Tolcapone: a review of its use in the management of Parkinson's disease.
Keating GM; Lyseng-Williamson KA
CNS Drugs; 2005; 19(2):165-84. PubMed ID: 15697329
[TBL] [Abstract][Full Text] [Related]
7. Tolcapone, a selective catechol-O-methyltransferase inhibitor for treatment of Parkinson's disease.
Guay DR
Pharmacotherapy; 1999 Jan; 19(1):6-20. PubMed ID: 9917075
[TBL] [Abstract][Full Text] [Related]
8. A systematic review of catechol-0-methyltransferase inhibitors: efficacy and safety in clinical practice.
Marsala SZ; Gioulis M; Ceravolo R; Tinazzi M
Clin Neuropharmacol; 2012; 35(4):185-90. PubMed ID: 22805229
[TBL] [Abstract][Full Text] [Related]
9. Simultaneous MAO-B and COMT inhibition in L-Dopa-treated patients with Parkinson's disease.
Lyytinen J; Kaakkola S; Ahtila S; Tuomainen P; Teräväinen H
Mov Disord; 1997 Jul; 12(4):497-505. PubMed ID: 9251066
[TBL] [Abstract][Full Text] [Related]
10. COMT inhibition: a new treatment strategy for Parkinson's disease.
Kurth MC; Adler CH
Neurology; 1998 May; 50(5 Suppl 5):S3-14. PubMed ID: 9591516
[TBL] [Abstract][Full Text] [Related]
11. [COMT inhibition with tolcapone].
Nervenarzt; 1996 Jul; 67(7 Suppl Comt-hemmu):1-8. PubMed ID: 9404535
[No Abstract] [Full Text] [Related]
12. Influence of COMT inhibition on levodopa pharmacology and therapy.
Goetz CG
Neurology; 1998 May; 50(5 Suppl 5):S26-30. PubMed ID: 9591519
[TBL] [Abstract][Full Text] [Related]
13. Effects of tolcapone, a catechol-O-methyltransferase inhibitor, on motor symptoms and pharmacokinetics of levodopa in patients with Parkinson's disease.
Yamamoto M; Yokochi M; Kuno S; Hattori Y; Tsukamoto Y; Narabayashi H; Tohgi H; Mizuno Y; Kowa H; Yanagisawa N; Kanazawa I
J Neural Transm (Vienna); 1997; 104(2-3):229-36. PubMed ID: 9203084
[TBL] [Abstract][Full Text] [Related]
14. [Inhibition of the COMPT with entacapone in the treatment of motor fluctuations in Parkinson disease].
Kulisevsky J
Neurologia; 1999; 14(7):349-58. PubMed ID: 10570622
[TBL] [Abstract][Full Text] [Related]
15. Tolcapone in Parkinson's disease: liver toxicity and clinical efficacy.
Borges N
Expert Opin Drug Saf; 2005 Jan; 4(1):69-73. PubMed ID: 15709899
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetic-pharmacodynamic modeling of levodopa in patients with advanced Parkinson disease.
Adamiak U; Kaldonska M; Klodowska-Duda G; Wyska E; Safranow K; Bialecka M; Gawronska-Szklarz B
Clin Neuropharmacol; 2010 May; 33(3):135-41. PubMed ID: 20216409
[TBL] [Abstract][Full Text] [Related]
17. Entacapone. A review of its use in Parkinson's disease.
Holm KJ; Spencer CM
Drugs; 1999 Jul; 58(1):159-77. PubMed ID: 10439935
[TBL] [Abstract][Full Text] [Related]
18. [Entacapone: is it useful as complimentary treatment with levodopa?].
Burguera JA; Grandas F; Horga de la Parte JF; Luquin R; Martí F; Matías-Guiu J; Obeso JA; Kulisevsky J
Rev Neurol; 1999 Apr 16-30; 28(8):817-34. PubMed ID: 10363328
[TBL] [Abstract][Full Text] [Related]
19. Modifications of plasma and platelet levels of L-DOPA and its direct metabolites during treatment with tolcapone or entacapone in patients with Parkinson's disease.
Blandini F; Nappi G; Fancellu R; Mangiagalli A; Samuele A; Riboldazzi G; Calandrella D; Pacchetti C; Bono G; Martignoni E
J Neural Transm (Vienna); 2003 Aug; 110(8):911-22. PubMed ID: 12898346
[TBL] [Abstract][Full Text] [Related]
20. Issues important for rational COMT inhibition.
Dingemanse J
Neurology; 2000; 55(11 Suppl 4):S24-7; discussion S28-32. PubMed ID: 11147507
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
